Literature DB >> 24612943

Adverse event management in mass drug administration for neglected tropical diseases.

Arthur Caplan1, Amanda Zink2.   

Abstract

The ethical challenges of reporting and managing adverse events (AEs) and serious AEs (SAEs) in the context of mass drug administration (MDA) for the treatment of neglected tropical diseases (NTDs) require reassessment of domestic and international policies on a global scale. Although the World Health Organization has set forth AE/SAE guidelines specifically for NTD MDA that incorporate suspected causality, and recommends that only SAEs get reported in this setting, most regulatory agencies continue to require the reporting of all SAEs exhibiting even a merely temporal relationship to activities associated with an MDA program. This greatly increases the potential for excess "noise" and undue risk aversion and is not only impractical but arguably unethical where huge proportions of populations are being treated for devastating diseases, and no good baseline exists against which to compare possible AE/SAE reports. Other population-specific variables that might change the way drug safety ought to be assessed include differing efficacy rates of a drug, background morbidity/mortality rates of the target disease in question, the growth rate of the incidence of disease, the availability of rescue or salvage therapies, and the willingness of local populations to take risks that other populations might not. The fact that NTDs are controllable and potentially eradicable with well-tolerated, effective, existing drugs might further alter our assessment of MDA safety and AE/SAE tolerability. At the same time, diffuseness of population, communication barriers, lack of resources, and other difficult surveillance challenges may present in NTD-affected settings. These limitations could impair the ability to monitor an MDA program's success, as well as hinder efforts to obtain informed consent or provide rescue therapy. Denying beneficial research interventions and MDA programs intended to benefit millions requires sound ethical justification based on more than the identification of and rote response to AEs and SAEs.
Copyright © 2014 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Keywords:  adverse events; benefit; developing nation; research ethics; risk

Mesh:

Year:  2014        PMID: 24612943     DOI: 10.1016/j.clinthera.2014.02.002

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

1.  Selecting the right tool for the job.

Authors:  Arthur L Caplan; Carolyn Plunkett; Bruce Levin
Journal:  Am J Bioeth       Date:  2015       Impact factor: 11.229

2.  Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine.

Authors:  Mariana Pereira; Guy Caljon; Maria João Gouveia; Louis Maes; Nuno Vale
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-27

3.  Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.

Authors:  Abbie Barry; Sten Olsson; Christabel Khaemba; Joseph Kabatende; Tigist Dires; Adam Fimbo; Omary Minzi; Emile Bienvenu; Eyasu Makonnen; Appolinary Kamuhabwa; Margaret Oluka; Anastasia Guantai; Eugène van Puijenbroek; Ulf Bergman; Alex Nkayamba; Michael Mugisha; Parthasarathi Gurumurthy; Eleni Aklillu
Journal:  Int J Environ Res Public Health       Date:  2021-02-17       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.